Specifically, we generated a Cldn3 knockdown of 85% and 97% for PC3 and LNCaP human prostate cancer cells, respectively, when treated with siCldn3_4 and a Cldn4 knockdown of > 99% and 98% for PC3 and LNCaP human prostate cancer cells, respectively, when treated with siCldn4_1. This evidence concerns the gene CLDN4 and prostate carcinoma.